First AD

Second AD

P16-mutation carriers are at extremely high risk for developing melanoma. Many high-risk melanoma clinics worldwide are reporting genetic test results, and clinical testing also is increasing in the United States. There are currently no guidelines regulating genetic testing in the United States, but melanoma genetics experts are working to develop meaningful guidelines that will, hopefully, be published in early 2008.